|
Bay Area Tumor Institute CCOP
|
5U10CA045461-20
|
$521,201
|
$10,424
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
SPORE in Lymphoma
|
3P50CA126752-03S1
|
$371,941
|
$111,582
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
5P50CA126752-03
|
$2,266,618
|
$679,985
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
Chimeric T Cell for Therpay of Hodgkin Disease
|
5R01CA131027-02
|
$318,513
|
$318,513
|
SAVOLDO, BARBARA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Epstein-Barr Virus Nuclear Proteins in B Cell Growth Transformation
|
5R01CA047006-22
|
$560,086
|
$280,043
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus LMP-1 Mediated Oncogenicity
|
5R01CA085180-09
|
$725,501
|
$725,501
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Pathogenesis of Epstein-Barr Virus Infection
|
5R01CA068051-14
|
$417,501
|
$41,750
|
WANG, FREDERICK
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Delaware/Christiana Care CCOP
|
5U10CA045418-23
|
$1,282,700
|
$12,827
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
City of Hope Lymphoma SPORE
|
3P50CA107399-05S1
|
$1,079,832
|
$539,916
|
forman, stephen
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S1
|
$124,531
|
$1,245
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S2
|
$100,000
|
$1,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S5
|
$143,383
|
$1,434
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-45
|
$11,688,901
|
$116,889
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Enhanced Self-Appraisal After Cancer: A Bias in Survivors' Self-Report?
|
1R03CA134159-01A2
|
$84,552
|
$84,552
|
Recklitis, Christopher
|
DANA-FARBER CANCER INSTITUTE
|
|
Duluth Community Clinical Oncology Program
|
5U10CA035269-26
|
$747,046
|
$14,941
|
Nikcevich, Daniel
|
DULUTH CLINIC, LTD.
|
|
EORTC DATA CENTER
|
5U10CA011488-39
|
$809,323
|
$24,280
|
Sylvester, Richard
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
FASEB Conference-Hematological Malignancies
|
5R13CA117424-03
|
$9,710
|
$1,942
|
ZHANG, DONG-ER
|
FEDERATION OF AMER SOC FOR EXPER BIOLOGY
|
|
Community Clinical Oncology Program: FL Pediatric CCOP
|
5U10CA035157-26
|
$382,772
|
$30,622
|
TALBERT, JAMES
|
FLORIDA ASSN OF PEDIATRIC TUMOR PROG
|
|
Mixed Hematopoietic Chimerism After Stem Cell Allografts
|
2P01CA078902-11
|
$1,991,605
|
$59,748
|
STORB, RAINER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Towards a Mouse Model of Classical Hodgkin's Disease and PTLD
|
2R01CA098285-06A1
|
$487,828
|
$487,828
|
RAJEWSKY, KLAUS
|
IMMUNE DISEASE INSTITUTE, INC.
|
|
Iowa Oncology Research Association
|
5U10CA035101-24
|
$865,544
|
$17,311
|
Behrens, Robert
|
IOWA ONCOLOGY RESEARCH ASSOCIATION
|
|
SPORE in Lymphoma
|
3P50CA096888-05S2
|
$304,005
|
$152,003
|
AMBINDER, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
|
EBV Genome Expression:Localization of Specific Functions
|
5R01CA030356-28
|
$330,440
|
$33,044
|
HAYWARD, S
|
JOHNS HOPKINS UNIVERSITY
|
|
Bone Marrow Transplantation in Human Disease
|
5P01CA015396-34
|
$3,012,562
|
$753,141
|
JONES, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
|
Novel Biologic Therapies for Hodgkin's Lymphoma
|
5K23CA124465-02
|
$140,940
|
$140,940
|
KASAMON, YVETTE
|
JOHNS HOPKINS UNIVERSITY
|
|
Dose-Response in Radionuclide Therapy
|
5R01CA116477-04
|
$397,575
|
$131,200
|
SGOUROS, GEORGE
|
JOHNS HOPKINS UNIVERSITY
|
|
microRNAs Dysregulated by HMG-I in Neoplastic Transformation
|
5F31CA134209-02
|
$41,176
|
$20,588
|
Smail, Shamayra
|
JOHNS HOPKINS UNIVERSITY
|
|
LSUHSC Minority-Based Community Clinical Oncology Program
|
2U10CA063845-11
|
$710,000
|
$14,200
|
VEITH, ROBERT
|
LOUISIANA STATE UNIV HSC NEW ORLEANS
|
|
Marshfield Community Clinical Oncology Program
|
5U10CA035412-26
|
$926,378
|
$18,528
|
Weiss, Matthias
|
MARSHFIELD CLINIC RESEARCH FOUNDATION
|
|
GVL without GVHD across HLA barriers: Translational Studies
|
5P01CA111519-04
|
$1,902,623
|
$633,573
|
Sykes, Megan
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Signal transduction inhibitor therapy for Lymphoma
|
5R01CA127433-03
|
$336,563
|
$168,282
|
Witzig, Thomas
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
MCG Minority-Based Community Clinical Oncology Program
|
3U10CA107586-06S1
|
$100,000
|
$2,000
|
Jillella, Anand
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
|
MCG Minority-Based Community Clinical Oncology Program
|
5U10CA107586-06
|
$550,477
|
$11,010
|
Jillella, Anand
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
|
Research Management and Support
|
RMS2009 [E]
|
$350,982,837
|
$35,000
|
N/A
|
National Cancer Institute
|
|
Children's Oncology Group Statistics and Data Center Grant
|
5U10CA098413-07
|
$5,725,544
|
$801,576
|
ANDERSON, JAMES
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Community Clinical Oncology program Research Base
|
5U10CA095861-08
|
$2,126,089
|
$297,652
|
POLLOCK, BRAD
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Children's Oncology Group Chair's Grant
|
3U10CA098543-07S3
|
$749,797
|
$104,972
|
REAMAN, GREGORY
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Children's Oncology Group Chair's Grant
|
5U10CA098543-07
|
$27,646,062
|
$3,870,449
|
REAMAN, GREGORY
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Support for Human Specimen Banking in NCI-Supported Cancer Clinical Trials
|
5U24CA114766-05
|
$1,195,618
|
$119,562
|
REAMAN, GREGORY
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Infections, immunity, and inflammation in cancer
|
ZIA CP010150-10419
|
$51,543
|
$51,543
|
A Engels, Eric
|
DCEG (NCI)
|
|
Family Studies
|
ZIA CP004410-08167
|
$160,190
|
$152,181
|
A Tucker, Margaret
|
DCEG (NCI)
|
|
Activation of Proto-Oncogenes by Chromosomal Translocation
|
ZIA SC 010378
|
$279,762
|
$97,917
|
Aplan, Peter
|
CCR (NCI)
|
|
Studies of Medical Radiation and Other Therapeutic Agents
|
ZIA CP010131-04020
|
$2,310
|
$231
|
Berrington, Amy
|
DCEG (NCI)
|
|
Studies of Medical Radiation and Other Therapeutic Agents
|
ZIA CP010131-04021
|
$64,057
|
$3,843
|
Berrington, Amy
|
DCEG (NCI)
|
|
Studies of Medical Radiation and Other Therapeutic Agents
|
ZIA CP010131-04033
|
$172,949
|
$17,295
|
Berrington, Amy
|
DCEG (NCI)
|
|
Developing Immunoablative Regimens for the Engraftment of Allogeneic HSCT
|
ZIA BC 010698
|
$167,837
|
$25,176
|
Bishop, Michael
|
CCR (NCI)
|
|
Relapse after Allogeneci Hematopoietic Stem Cell Transplantation
|
ZIA BC 011239
|
$167,837
|
$33,567
|
Bishop, Michael
|
CCR (NCI)
|
|
Optimizing the Graft-Versus-Tumor Effect in Allogeneic HSCT
|
ZIA SC 010365
|
$223,783
|
$44,757
|
Bishop, Michael
|
CCR (NCI)
|
|
CLL Families-Mayo
|
ZIA CP004410-10312
|
$213,286
|
$10,664
|
Caporaso
|
DCEG (NCI)
|
|
Antibody-based therapeutics and vaccines against AIDS
|
ZIA BC 011155
|
$287,030
|
$143,515
|
Dimitrov, Dimiter
|
CCR (NCI)
|
Total relevant funding to Hodgkins disease for this search: $18,224,261
|